(1) Background and objectives: Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality throughout the world. In addition to genetics, increasing evidence suggests that Vitamin D (VitD) might be involved in different pathogenic mechanisms in COPD. Furthermore, the prevalence of VitD insufficiency is exceptionally high in COPD patients and increases with the severity. Based on the above, we first tested the relation between the top 10 single nucleotide polymorphisms from genome-wide association studies and the risk of COPD. Then, we investigated whether VitD levels might also have a role in COPD. A meta-analysis followed, combining our participants with previously published European and non-European populations (15,716 cases and 48,107 controls). (2) Methods: 631 Lebanese participants were recruited, of which ~28% were affected with COPD. Demographic and clinical data were collected, and DNA was genotyped using Kompetitive allele-specific PCR (KASPT). Adjusted multiple logistic regression models were used. Bonferroni corrections were also applied. The statistical power was also assessed. (3) Results: Both rs6837671A>G in and VitD levels were significantly associated with increased risk of COPD (OR = 1.75, = 0.01, and OR = 3.10, < 0.001 respectively). An interaction between rs6837671A>G in and VitD levels, which increased COPD risk, was found (OR = 3.35 and < 0.001). The meta-analysis showed that rs6837671G increases COPD risk in populations from different origins; Europeans, Asians, and now in Middle-Eastern. (4) Conclusions: Our results suggest that rs6837671A>G in is a trans-ethnic genetic variant that interact with VitD to affect COPD.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7912529 | PMC |
http://dx.doi.org/10.3390/jpm11020084 | DOI Listing |
J Clin Med Res
January 2025
Department of Physiology, Faculty of Science, University of Karachi, Karachi, Pakistan.
Background: Association of serum vitamin D (vitD) with leptin (Lep) and tumor necrosis factor-alpha (TNF-α) is not precisely known in overweight hypertensive (OW-HT) postmenopausal (PMP) women. Hence, the present study was carried out to investigate the body mass index (BMI)-based correlation of serum vitD with Lep and TNF-α in OW-HT PMP women.
Methods: Women subjects in their early PMP (n = 346, age: 51 - 60 years) categorized into three groups had main inclusion criteria of specified range of age, BMI and blood pressure (BP).
Mol Biol Rep
December 2024
Department of Physiology, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Background: The role of 1,25-dihydroxyvitamin-D3 (VitD) and sirtuin-1 (SIRT1) in mitigating pathological cardiac remodeling is well recognized. However, the potential for SIRT1 to mediate the inhibitory effects of VitD on angiotensin II (Ang II) -induced hypertrophy in H9c2 cardiomyoblasts remains unclear.
Methods: H9c2 cardiomyoblasts were exposed to Ang II or a combination of VitD and Ang II, both in the absence and presence of SIRT1-specific siRNA.
Curr Issues Mol Biol
December 2024
Department of Neurology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-055 Katowice, Poland.
Studies suggest that vitamin D (VitD) may reduce oxidative stress (OS) in multiple sclerosis (MS) patients. This study aimed to compare the effects of various VitD doses on OS in relapsing-remitting MS (RRMS). A 6-month supplementation was introduced using two doses of VitD: 2000 IU/day in the high-dose group (HD, = 23) and 15,960 IU/month in the low-dose group (LD, = 29).
View Article and Find Full Text PDFJDS Commun
November 2024
Institute for Global Food Security, School of Biological Sciences, Queen's University, Belfast, United Kingdom BT9 5DL.
Investigations into the role of vitamin D (vitD) in the immune response of cattle are limited. The objectives of this study were therefore to investigate the association between circulating vitD concentration, tuberculosis (TB) vaccination, and infection outcomes in 24 dairy calves (<8 wk old) that were housed throughout and fed a BW-based allowance. The study design incorporated 2 phases: vaccination (experimental wk 0-52) and experimental infection phase (wk 52-65).
View Article and Find Full Text PDFFront Pharmacol
November 2024
Department of Orthopedic Trauma, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Objective: There is currently no consensus on whether the combination therapy of Vitamin D (VitD) and bisphosphonates offers superior efficacy compared to monotherapy in the treatment of postmenopausal osteoporosis. The aim of this study is to conduct a meta-analysis of recent relevant research to synthesize the available evidence and further investigate whether the combined use of VitD and bisphosphonates is superior to monotherapy in treating osteoporosis in postmenopausal women.
Methods And Results: We systematically searched PubMed, EMBASE, the Cochrane Library, and Web of Science for randomized controlled trials (RCTs) comparing the effects of monotherapy with VitD or bisphosphonates their combination therapy in the treatment of postmenopausal osteoporosis, up to 1 February 2024.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!